Ligand Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/31/2023
Ligand Pharmaceuticals Stock Forecast and Price Target
Ligand Pharmaceuticals has an average price target of $158.50 recently offered by two notable experts for 2023, which would represent a potential upside of approximately 119.74% from the last closing price in May, 2023 if reached. This potential increase is based on a high estimate of $310.00 and a low estimate of $130.00. Even if you are not interested in LGND stock, you should still be aware of its competitors.
119.74% Upside
Ligand Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Price for Ligand Pharmaceuticals has grown by 107.77%, going from $70.95 to $147.40. According to 0 analysts, Ligand Pharmaceuticals's Fair Value will fall by 30.12% in the next year, reaching $103.01. Professionals believe that By 2030, Ligand Pharmaceuticals's Fair Value will fall to $111.44 – a 24.40% decrease from its current value.
Ligand Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Ligand Pharmaceuticals has grown by 130.40%, going from $120.28M to $277.13M. According to 0 analysts, Ligand Pharmaceuticals's Revenue will fall by 33.65% in the next year, reaching $183.88M. Professionals believe that By 2030, Ligand Pharmaceuticals's Revenue will fall to $203.34M – a 26.62% decrease from its current value.
.jpg)
Ligand Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Ligand Pharmaceuticals's Free Cash Flow has grown, increasing from $-31.89M to $70.04M – an increase of 319.63%. For the following year, the 0 analysts predict that Ligand Pharmaceuticals's Free Cash Flow will drop by 73.49%, reaching $18.57M. In 2030, the professionals' prediction is that LGND's Free Cash Flow will decrease by 26.65%, reaching $51.37M.
Ligand Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Ligand Pharmaceuticals's Net Income has decreased by 90.92%, going from $629.30M to $57.14M. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $4.04B – an increase of 6978.79%. By 2030, professionals predict that Ligand Pharmaceuticals's Net Income will decrease by 1420771647.42%, to $-811.83T.
Ligand Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Ligand Pharmaceuticals's EBITDA has increased by 142.67% In the last two years, going from $38.01M to $92.24M. In the following year, the 0 analysts surveyed believe that Ligand Pharmaceuticals's EBITDA will decrease by 36.44%, reaching $58.63M. According to professionals, by 2030, Ligand Pharmaceuticals's EBITDA will have decreased by 28.30%, falling down to $66.14M.
Ligand Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Ligand Pharmaceuticals's EBIT has grown, increasing from $-5.72M to $41.30M – a growth of 822.03%. The next year, 0 experts forecast that Ligand Pharmaceuticals's EBIT will decrease by 58.97%, reaching $16.94M. In 2030, professionals predict that Ligand Pharmaceuticals's EBIT will decrease by 35.60%, reaching $26.60M.
Ligand Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, EPS for Ligand Pharmaceuticals has grown by 107.77%, going from $3.09 to $6.42. According to 0 analysts, Ligand Pharmaceuticals's EPS will fall by 30.12% in the next year, reaching $4.49. Professionals believe that By 2030, Ligand Pharmaceuticals's EPS will fall to $4.85 – a 24.40% decrease from its current value.
Site Navigation
.jpg)